Professor Farzin Farzaneh

King’s College London
Professor of Molecular Medicine, Director of Cell and Gene Therapy

Farzin Farzaneh D.Phil., FRCPath., FRSB
Professor of Molecular Medicine, and Director of Cell and Gene Therapy – King’s.
Consultant in Specialist Medicine, King’s College Hospital

Farzin Farzaneh holds the Chair of Molecular Medicine at King’s College London. He has published over 250 research articles with an average citation of over 30, and an Impact Factor of 47. He has run a licensed GMP facility at King’s College London, since 2001, for the production of cell and gene therapy based investigational medicinal products. Farzin has extensive industrial and academic collaborations, including research council, charitable and pharmaceutical sponsorships of over £25M. He is appointed by the Commission on Human Medicines, as a member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group since 2016. He is the recipient of 2016 Distinguished Scientist Award of the US Society for Experimental Biology & Medicine.

dont miss

Advanced Therapy Medicinal Products (ATMPs) for achievement of deeper and longer lasting immune mediated cancer remission

Cell and gene based therapy of cancer is making major improvements to the treatment of cancer. The development of new strategies for the development of chimeric antigen receptor T cells, genetically modified cancer cell vaccines and therapeutic cancer vaccines for the specific induction of cellular immunity will be described.

EVEN MORE SEMINARS

  • Lucinda Billingham: Speaking at the Oncology Convention

    Lucinda Billingham
    University of Birmingham - Cancer Research Clinical Trials Unit

    National Lung Matrix Trial: testing multiple novel targeted treatments

  • Mr Hamish Clouston: Speaking at the Oncology Convention

    Mr Hamish Clouston
    The Christie NHS Foundation Trust

    Surgical Management of Advanced Colonic and Rectal Malignancies.

  • Chris Carrigan: Speaking at the Oncology Convention

    Chris Carrigan
    Bowel Cancer Intelligence UK

    Patient Engagement in the uses of Patient Data

  • Professor Anthony Howell: Speaking at the Oncology Convention

    Professor Anthony Howell
    The University of Manchester / The Christie NHS Foundation Trust

    Improving risk estimation of breast cancer

  • Malcolm Wilson: Speaking at the Oncology Convention

    Malcolm Wilson
    The Colorectal & Peritoneal Oncology Centre, The Christie Hospital NHS Foundation Trust, Manchester

    Cytoreduction and HIPEC in the treatment of peritoneal disease from appendiceal and colorectal tumours